Essential thrombocythemia (ET) is a blood condition where there is uncontrolled production of blood cells by the bone marrow. People with essential thrombocythemia will have too many platelets which results in a higher risk of forming blood clots.
Patients with ET present in different ways.
For many, they may not have any symptoms, but abnormalities were detected after a routine blood test.
Many patients with essential thrombocythemia are recognized incidentally during routine blood test.
Essential thrombocythemia occurs when there is a mutation in genes which is involved in the regulation of blood cell production. The cause of the gene mutation is unknown and is usually not an inheritable mutation.
To make a diagnosis of essential thrombocythemia, patients will require blood tests including a full blood count and tests for the mutations (gene alterations) found with MPN. The gene alteration usually associated are Jak2 V617F, Calreticulin (CALR), and MPL.
Patients may need a bone marrow aspiration and trephine biopsy, as well as additional tests to exclude other causes of elevated blood counts.
The treatment of essential thrombocythemia includes
Good control of pre-existing conditions such as high blood pressure, high cholesterol and diabetes mellitus also helps to decrease the risk of blood clot.
A healthy lifestyle including regular exercise and a healthy diet is also recommended.
In patients who require reduction of the platelet count, this can be achieved with medication: hydroxyurea, anagrelide, PEGylated interferon.
Young patients with no history of previous blood clots generally do not need medications to reduce the platelet count.
Subscribe to our mailing list to get the updates to your email inbox...
SHP-Head Office, 167 Jalan Bukit Merah Connection One (Tower 5), #15-10, Singapore 150167+65 6236 4800